CDKN2A and endometrial carcinoma: Stromal p16 expression was absent or weak in benign lesions, whereas the majority of malignant lesions exhibited diffuse and moderate-to-strong p16 immunoreactivity, suggesting that stromal p16 expression promotes the development and progression of endometrial carcinoma.